This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Assessment of Safety and Pharmacokinetics of a Low Dose of Methotrexate in Healthy Adult Male Kenyan Volunteers

This study has been completed.
University of Oxford
Information provided by (Responsible Party):
KEMRI-Wellcome Trust Collaborative Research Program Identifier:
First received: November 13, 2008
Last updated: April 23, 2012
Last verified: April 2012
Previous investigations indicate that methotrexate, an old anticancer drug, could be used at low doses to treat malaria. This is a phase I evaluation to assess the safety and pharmacokinetic profile of this drug in healthy adult male Kenyan volunteers.

Condition Intervention Phase
Malaria Drug: Methotrexate Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1 Assessment of Safety and Pharmacokinetics of a Low Dose of Methotrexate in Healthy Adult Male Kenyan Volunteers

Resource links provided by NLM:

Further study details as provided by KEMRI-Wellcome Trust Collaborative Research Program:

Primary Outcome Measures:
  • Clinical safety parameters:oral ulcers, GI tract disturbance,hematology, renal hepatic & other unsolicited safety AEs [ Time Frame: 42 days ]

Secondary Outcome Measures:
  • Pharmacokinetics of Methotrexate assessed by repeated measurement of blood concentrations [ Time Frame: 42 days ]

Enrollment: 25
Study Start Date: March 2009
Study Completion Date: August 2009
Primary Completion Date: August 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Methotrexate
Oral methotrexate 5mg once daily for 5 consecutive days
Drug: Methotrexate
Oral methotrexate 5mg once daily for 5 consecutive days
Other Name: Methotrexate Lerdele

Detailed Description:

Background Currently the control of malaria rests on the use of chemotherapy. However, the development of resistance to common used drugs represents a major public concern. Thus, the investigators need to develop new and cheap drugs. The investigators have discovered that the old drug methotrexate (MTX), which is used in the treatment of cancer and rheumatoid arthritis (RA), is very active against malaria parasites, including those that are resistant to existing antimalarials.

In the treatment of RA, MTX is used weekly at a low dose for several years. At dose, MTX is safe and well tolerated in human and children. This low dose of MTX will also kill malaria parasite in human. Thus, want to study MTX as an antimalarial. As part of this study, the investigators need to establish whether at the dose the investigators want it, 5 mg per days for 5 days, the drug is safe and well tolerated in 25 Kenyan adult volunteers. This result of this study will inform us on the use of MTX in the treatment of malaria in children.

What questions are the investigators trying to answer?

The investigators are trying to assess the safety of 5mg dose per day for 5

Where is the study taking place, how many people does it involve and how are they selected?

The study is taking place at KEMRI, Centre for Clinical Research, Nairobi. The study will involve 25 healthy adults.

What does the study involve for those who are taking part? Healthy adult males will be invited to join the study. A small blood sample will be collected from the arm to assess how the body is responding, the state of blood, liver and kidney functioning before and after the administration of the drug. This sample will also be used to rule out the presence of other infections such as HIV and Hepatitis.

Study patients will be given MTX every day for 5 days. During the days of Hospitalization patients will be assessed by physical examination, and tests to check for their liver function on day 1 and 5. Patients will then be followed up for a minimum of 42 days and will be seen at the clinics on days 7, 14, 28 and 42. The state of blood, liver and kidney will be done only before starting treatment and on day 28. Patients will also be required to undergo more samples to assess the level of the drug in their blood at different times from starting of treatment.

What are the benefits and risks/costs of the study for those involved Study subjects will receive full medical consultation and treatment through-out the study period. Long term benefits could be the addition of MTX to the list of antimalaria drugs available for treatment of non serious malaria. During the follow up period they will have the opportunity for their health to be followed up closely with a dedicated team of clinicians.

MTX has been used extensively at low dose in the treatment of RA. The drug is safe and well tolerated in human and children. However, when used on a chronic basis, few adverse reactions have so far been reported, mostly gastrointestinal upsets associated with nausea and vomiting. The risk this sign to occur is very small since we will use the drug for 5 days only.

How will the study benefit society? This study may help in development of MTX as a cheap, safe and easy to use drug in the treatment of malaria to add to the already available list of drugs.


Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Males, Aged > 18 -< 55years old; weighing 55-75 kg
  • Serum haemoglobin >10g/dl
  • HIV negative status
  • Written informed consent from the study subject.

Exclusion Criteria:

  • Severe underlying conditions such as malnutrition (W/H <70%), clinically suspected cardiac, renal, or hepatic diseases, suspected AIDS, or severe injury.
  • Presence of any concomitant illnesses such malaria, lower respiratory tract infections (LRTI), acute bloody or non-bloody diarrhoeas, or other as acute infections
  • History of treatment with antimalarial drugs within the last 2 weeks
  • History of treatment with aspirin or any non-steroidal-anti-inflammatory agent or trimethoprim and co-trimoxazole within the last 7 days.
  • Any ongoing medication.
  • Abnormal clinical chemistry or haematological finding
  • Alcohol/drugs intake
  • Any other reason in the recruiting clinician's opinion that makes the individual unsuitable for taking part in a clinical trial.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00791531

Kenya Medical Research Institute, Center for Clinical Research
Nairobi, Kenya, 00200
Sponsors and Collaborators
KEMRI-Wellcome Trust Collaborative Research Program
University of Oxford
Principal Investigator: Alexis Nzila, Msc KEMRI-Wellcome Trust Collaborative Research Program
  More Information

Responsible Party: KEMRI-Wellcome Trust Collaborative Research Program Identifier: NCT00791531     History of Changes
Other Study ID Numbers: SSC1464
Study First Received: November 13, 2008
Last Updated: April 23, 2012

Keywords provided by KEMRI-Wellcome Trust Collaborative Research Program:

Additional relevant MeSH terms:
Protozoan Infections
Parasitic Diseases
Abortifacient Agents, Nonsteroidal
Abortifacient Agents
Reproductive Control Agents
Physiological Effects of Drugs
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Dermatologic Agents
Enzyme Inhibitors
Folic Acid Antagonists
Immunosuppressive Agents
Immunologic Factors
Antirheumatic Agents
Nucleic Acid Synthesis Inhibitors processed this record on August 18, 2017